CrushSCI.com
Journal Selection & Manuscript Polishing Services
CLINICAL CANCER RESEARCH 临时占位封面 Medicine
Back to journal directory

Review Cycle Records

CLINICAL CANCER RESEARCH

American Association for Cancer Research SCIE Non-OA
2026 Emerging Zone 12025 CAS Zone 1 TOP2025 JCR Q1
227.2Average days
204Median days
133Fastest days
344Longest days
2,7602025 publications

Paper Review Records

All Paper Review Records

5 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

160 days

Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics

AuthorsKiwan Kim; Seong-Won Song; Yeongha Jeon; Soyoung Choi; Jiyoun Choi; Sungmin Jun; Ju-Hwang Park; Song-Jae Lee; Nayoung Han; Yun-Sik Dho; Sang-Hoon Shin; Heon Yoo; Kyu-Chang Wang; Ho-Shin Gwak

Affiliations1. 1R&D center, CellabMED Inc., Seoul, Republic of Korea.; 2. 2CellabMED Inc., Seoul, Republic of Korea.; 3. 3CGT center, CellabMED Inc., Seoul, Republic of Korea.; 4. Samsung Medical Center 4 Department of Pathology and Translational Genomics, , Seoul, Republic of Korea.; 5. National Cancer Center 5 Neuro-oncology clinic, , Goyang, Republic of Korea.; 6. 6Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Republic of Korea.

Source PDF DOI Publisher page
295 days

DNMT3B Plays Antagonistic Roles with SMARCB1 and Is a Targetable Vulnerability in Rhabdoid Tumors

AuthorsCéline Chauvin; Ryszard Wimmer; Ludovica Brunetti; Joanna Cyrta; Ana Boranijasevic; Mamy Andrianteranagna; Julien Masliah-Planchon; Kévin Beccaria; Sandrina Turczynski; Grégory Thomson; Maëva Veyssière; Rachida Bouarich-Bourimi; Zhi-Yan Han; Owen Hoare; Aurore Coulomb; Mylène Bohec; Sylvain Baulande; Gaëlle Pierron; Olivier Delattre; Arnault Tauziède-Espariat; Nicolas Servant; Alexandre Baffet; Franck Bourdeaut

Affiliations1. 1INSERM U1330, Childhood Oncology Research Unit, SIREDO Oncology Center, Institut Curie Research Center, Paris, France.; 2. Institut Curie 2 , CNRS UMR144, PSL Research University, Sorbonne University, Paris, France.; 3. Institut Curie 3 Department of Pathology, , PSL Research University, Paris, France.; 4. Institut Curie 4 INSERM U900, Bioinformatics, Biostatistics, Epidemiology and Computational Systems Unit, , Mines Paris Tech, PSL Research University, Institut Curie Research Center, Paris, France.; 5. 5Somatic Genetic Unit, Department of Pathology, Diagnostic and Theranostic Medecine, Institut Curie Hospital, Paris, France.; 6. 6Department of Pediatric Neurosurgery, Necker Hospital, APHP, Université Paris Cité, Paris, France.; 7. Sorbonne Université 7 Department of Pathology, Hôpital Armand Trousseau, Assistance-Publique Hôpitaux de Paris, , Paris, France.; 8. 8Single Cell Initiative, ICGex Next-Generation, PSL Research University, Institut Curie Research Center, Paris, France.; 9. 9Department of Neuropathology, GHU Paris Psychiatry and Neurosciences, Sainte-Anne Hospital, Paris, France.; 10. 10Institut national de la santé et de la recherche médicale (Inserm), Paris, France.; 11. 11Paris Cité University, Paris, France.

Source PDF DOI Publisher page
344 days

Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies

AuthorsS. Daniel Haldar; Meredith Wetzel; Jiayun Lu; Jae W. Lee; Hassan Sinan; Christopher D. Jakubowski; Fen Saj; Dean Pavlick; Ryon P. Graf; Julia Quintanilha; Gerald Li; Jerry Mitchell; Jeffrey S. Ross; Anirban Maitra; Milind Javle; Shubham Pant; Hao Wang; Richard Burkhart; Daniel A. Laheru; Elizabeth M. Jaffee; Elana J. Fertig; Elizabeth D. Thompson; Dimitrios N. Sidiropoulos; Luciane T. Kagohara; Nilofer S. Azad

Affiliations1. The University of Texas MD Anderson Cancer Center 1 Department of Gastrointestinal Medical Oncology, , Houston, Texas.; 2. 2Johns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.; 3. Sidney Kimmel Comprehensive Cancer Center 3 Department of Oncology, , , Baltimore, Maryland.; 4. Johns Hopkins University 3 Department of Oncology, , , Baltimore, Maryland.; 5. Sidney Kimmel Comprehensive Cancer Center 4 Division of Quantitative Sciences, Department of Oncology, , , Baltimore, Maryland.; 6. Johns Hopkins University 4 Division of Quantitative Sciences, Department of Oncology, , , Baltimore, Maryland.; 7. 5Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.; 8. Icahn School of Medicine at Mount Sinai 6 Elmhurst Hospital Center, , Queens, New York.; 9. 7Department of Oncology, Albert Einstein College of Medicine, Bronx, New York.; 10. Foundation Medicine 8 , Boston, Massachusetts.; 11. SUNY Upstate Medical University 9 , Syracuse, New York.; 12. 10Perlmutter Cancer Center, New York University Grossman School of Medicine, New York, New York.; 13. 11Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland.; 14. 12Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland.

Source PDF DOI Publisher page
133 days

FDA Approval Summary: Erdafitinib for FGFR3 -Altered Locally Advanced or Metastatic Urothelial Carcinoma

AuthorsWilliam F. Maguire; Elaine Chang; Flora Mulkey; Vicky Hsu; Huali Wu; Tien M. Truong; Dana Kappel; Jeffrey Kraft; Jingyu Yu; Xin Gao; William F. Pierce; Nam Atiqur Rahman; Mallorie H. Fiero; Laleh Amiri-Kordestani; R. Angelo de Claro; Daniel L. Suzman

Affiliations1. U.S. Food and Drug Administration 1 Center for Drug Evaluation and Research, , Silver Spring, Maryland.; 2. 2Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.

Source PDF DOI Publisher page
204 days

Targetable S100–RAGE Signaling Mediates Intrinsic Trastuzumab Deruxtecan Resistance in Metastatic Breast Cancer

AuthorsWenjuan Dong; Shiruo Wang; Bill Chan; Matthew Vasquez; Johnny Z.M. Cui; James Sampson; Caitlin Sannes; Wei Yang; Akshjot Puri; Jenny Chang; Hong Zhao; Xiaoxian Li; Stephen T.C. Wong

Affiliations1. 1Systems Medicine and Bioengineering Department, Houston Methodist Neal Cancer Center, Houston, Texas.; 2. 2Advanced Cellular and Tissue Microscopy Shared Resource, Houston Methodist Research Institute and Houston Methodist Neal Cancer Center, Houston, Texas.; 3. Texas A&M University 3 School of Engineering Medicine, , Houston, Texas.; 4. 4Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia.; 5. 5Houston Methodist Neal Cancer Center, Houston, Texas.; 6. 6Department of Medicine, Houston Methodist Hospital and Weill Cornell Medicine, New York, New York.; 7. East Carolina University 7 Department of Pathology and Laboratory Medicine, Brody School of Medicine, , Greenville, North Carolina.; 8. 8Department of Radiology, Houston Methodist Hospital and Weill Cornell Medicine, New York, New York.

Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review96.4 days

Median77 days

Contact CrushSCI

Contact CrushSCI

Leave your contact details so we can discuss your manuscript, editing needs, and submission plan.

Selected service: Paper Editing Service

Or leave your contact details

WhatsApp, Telegram, WeChat, and email are all optional, but at least one is required. Once received, we will contact you as soon as possible.